Metraipolis › archive › dc_bdc9e759e4e6
Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens — Europe PMC PMID:37815978
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37815978
- DOI
- 10.1371/journal.pone.0287126
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:01:21.875Z
- SHA-256 of the archived text
0efbb0d8622dee16e5061ed4ed48da9bfeb1de54940669997506f89dca45f3cd- Stable URL of this page
https://metraipolis.com/documento/dc_bdc9e759e4e6
How to cite
Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens — Europe PMC PMID:37815978 — Europe PMC (en), https://europepmc.org/article/MED/37815978 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_bdc9e759e4e6 (Metraipolis archive dc_bdc9e759e4e6, sha256 0efbb0d8622dee16e5061ed4ed48da9bfeb1de54940669997506f89dca45f3cd)
BibTeX
@misc{dcbdc9e759e4e6,
title = {Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens — Europe PMC PMID:37815978},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37815978},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_bdc9e759e4e6; sha256 0efbb0d8622dee16e5061ed4ed48da9bfeb1de54940669997506f89dca45f3cd},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37815978. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Androgen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and (in a substantial minority of cases) neuroendocrine prostate cancer (NEPC) is common. Identifying effective targeted therapies is challenging because of acquired resistance to established treatments and the vast heterogeneity of advanced prostate cancer (PC). To streamline the identification of potentially active prostate cancer therapeutics, we have developed an adaptable semi-automated protocol which optimizes cell growth and leverages automation to enhance robustness, reproducibility, and throughput while integrating live-cell imaging and endpoint viability assays to assess drug efficacy in vitro. In this study, culture conditions for 72-hr drug screens in 96-well plates were established for a large, representative panel of human prostate cell lines including: BPH-1 and RWPE-1 (non-tumorigenic), LNCaP and VCaP (ADPC), C4-2B and 22Rv1 (CRPC), DU 145 and PC3 (androgen receptor-null CRPC), and NCI-H660 (NEPC). The cell growth and 72-hr confluence for each cell line was optimized for real-time imaging and endpoint viability assays prior to screening for novel or repurposed drugs as proof of protocol validity. We demonstrated effectiveness and reliability of this pipeline through validation of the established finding that the first-in-class BET and CBP/p300 dual inhibitor EP-31670 is an effective compound in reducing ADPC and CRPC cell growth. In addition, we found that insulin-like growth factor-1 receptor (IGF-1R) inhibitor linsitinib is a potential pharmacological agent against highly lethal and drug-resistant NEPC NCI-H660 cells. This protocol can be employed across other cancer types and represents an adaptable strategy to optimize assay-specific cell growth conditions and simultaneously assess drug efficacy across multiple cell lines. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-10-10). Identificativi: PMID 37815978 · PMCID PMC10564233 · DOI 10.1371/journal.pone.0287126. Descrittori MeSH principali: Prostatic Neoplasms, Castration-Resistant. Pagina: https://europepmc.org/article/MED/37815978 — https://doi.org/10.1371/journal.pone.0287126. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:31:06.915Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.